Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001719406

NRXPW

NRX Pharmaceuticals, Inc.
—
Market cap$126.4M
High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on NRXPW right now — valuation, ownership and activity at a glance.
Market Cap
$126.4M
Cap Size
Micro Cap
Inst. Holders
2 funds
Inst. Value
$347.00
Inst. Activity
0 buys / 1 sells
SEC Reports
4
Price chart 30d -15.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$0.00$0.00–$0.00———$0.0B—
Next Q$0.00$0.00–$0.00———$0.0B—
Current FY$0.00$0.00–$0.00———$0.0B—
Next FY$0.00$0.00–$0.00———$0.3B—
Institutional ownership
Which big funds own NRXPW (from quarterly 13F filings) and who is adding or trimming.
2 institutional holders with $347.00 total value (23,606 shares) as of 2026-Q1. Top holders: UBS, WOLVERINE. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q1
FundSharesValue% TrackedLast move
UBS Group AG13$0.000.0%NEAR_EXIT -99.3%
WOLVERINE ASSET MANAGEMENT LLC23,593$347.00100.0%DOUBLED +290.7%
Recent position changes
FundActionPrevCurrentChangeValue
UBS Group AGNEAR_EXIT1,85213-99.3%—
UBS Group AGDOUBLED181,852+10188.9%$131.00
UBS Group AGNEAR_EXIT1,50018-98.8%$1.00
UBS Group AGADD1,0321,500+45.3%$128.00
WOLVERINE ASSET MANAGEMENT LLCDOUBLED5,19020,278+290.7%$1.4K
UBS Group AGTRIM3,9111,032-73.6%$73.00
WOLVERINE ASSET MANAGEMENT LLCTRIM15,3925,190-66.3%$664.00
UBS Group AGTRIM15,2513,911-74.4%$501.00
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NRXPW.
Shares short
5,154
Settlement May 15, 2026
Change vs prior
-83.1%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
All NRXPW filing & press-release reports (4)